New research finds Motor Neuron Disease drug safe and effective at low doses
New research from the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial has found that low-dose interleukin-2 (IL2LD) is both safe and effective for use on people with Motor Neurone Disease (MND), also known as amyotrophic lateral sclerosis (ALS) compared to placebo.
By NIHR Maudsley BRC at 12 May 2025